ATOS net incomeQ2 2026-$8.49M
ATOS net income was -$8.49M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.42M a year earlier. For the full fiscal 2025 it was -$34.77M, compared with -$25.50M in fiscal 2024.
Atossa Therapeutics Inc. (ATOS) financials
For the twelve months ended Jun 30, 2026, Atossa Therapeutics Inc. reported -$37.71M of net income.
- Net income, TTM
- -$37.71M
- Free cash flow, TTM
- -$35.78M
- EPS, diluted, TTM
- -$4.34
- Cash
- $26.09M
- Market cap
- $21.3M
FY2016FY2025
FY2018FY2025
ATOS revenue and earnings growth
ATOS EPSQ2 2026-$0.95
ATOS diluted EPS was -$0.95 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.98 a year earlier. For the full fiscal 2025 it was -$4.04, compared with -$3.04 in fiscal 2024.
ATOS free cash flowQ2 2026-$9.64M
ATOS free cash flow was -$9.64M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$7.26M a year earlier. For the full fiscal 2025 it was -$29.79M, compared with -$21.05M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $21.18M | $14.12M | $17.33M | $15.08M | $9.21M | $6.61M | $6.65M | $4.21M | $2.33M | $770.4K |
| Selling, general and admin | $15.96M | $13.50M | $14.04M | $12.61M | $11.31M | $8.00M | $10.62M | $7.22M | $4.86M | $6.48M |
| Operating income | -$37.14M | -$27.62M | -$31.38M | -$27.69M | -$20.52M | -$14.61M | -$17.27M | -$11.43M | -$7.65M | -$7.97M |
| Pre-tax income | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -$20.61M | -$17.83M | -$17.24M | -$11.40M | -$8.12M | -$6.37M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net income | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -$20.61M | -$17.83M | -$17.24M | -$11.40M | -$8.12M | -$6.37M |
| EPS, basic | -$4.04 | -$3.04 | -$3.60 | -$3.15 | -$2.70 | -$29.55 | -$30.45 | -$82.50 | -$164.55 | -$388.80 |
| EPS, diluted | -$4.04 | -$3.04 | -$3.60 | -$3.15 | -$2.70 | -$29.55 | -$30.45 | -$82.50 | -$164.55 | -$388.80 |
| Diluted shares | 8.6M | 8.4M | 8.4M | 8.4M | 7,796.667 | 753.933 | 566,464.267 | 277,183.067 | 64,984.867 | 16,373.789 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $41.30M | $71.08M | $88.46M | $110.89M | $136.38M | $39.55M | $12.58M | $10.38M | $7.22M | $3.08M |
| Current assets | $45.62M | $74.46M | $92.22M | $118.20M | $141.24M | $42.77M | $14.32M | $11.55M | $7.90M | $3.25M |
| Total assets | $47.61M | $76.44M | $96.25M | $123.53M | $141.26M | $42.84M | $14.49M | $11.72M | $8.16M | $4.14M |
| Current liabilities | $8.26M | $4.97M | $5.24M | $5.57M | $3.13M | $15.67M | $1.32M | $2.92M | $1.23M | $1.05M |
| Total liabilities | $8.26M | $4.97M | $5.24M | $5.57M | $3.13M | $15.67M | $1.33M | $2.92M | - | $1.05M |
| Shareholders' equity | $39.35M | $71.48M | $91.02M | $117.96M | $138.14M | $27.17M | $13.16M | $8.81M | $6.94M | $3.10M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.76M | -$21.03M | -$20.94M | -$20.76M | -$16.47M | -$11.57M | -$9.13M | -$8.96M | -$6.59M | -$5.37M |
| Capital expenditures | $23.0K | $19.0K | $14.0K | $27.0K | $9.0K | $9.0K | $7.6K | $110.9K | - | - |
| Free cash flow | -$29.79M | -$21.05M | -$20.95M | -$20.79M | -$16.48M | -$11.58M | -$9.14M | -$9.07M | - | - |
| Investing cash flow | -$23.0K | -$19.0K | -$14.0K | -$4.73M | -$9.0K | -$9.0K | -$7.6K | -$110.9K | - | -$9.2K |
| Financing cash flow | $0 | $3.67M | -$1.48M | $0 | $113.30M | $38.55M | $11.34M | $12.29M | $10.78M | $4.70M |
| Share repurchases | - | $0 | $1.48M | $0 | - | - | - | - | - | - |
| Stock-based compensation | $2.65M | $2.29M | $4.62M | $6.79M | - | - | - | - | - | - |
| Depreciation and amortization | - | - | - | $8.0K | $23.0K | $47.0K | $52.8K | $44.2K | $129.0K | $303.5K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -88.4% | -35.7% | -33.1% | -22.9% | -14.9% | -65.6% | -131.0% | -129.5% | -117.1% | -205.6% |
| Return on assets | -73.0% | -33.4% | -31.3% | -21.8% | -14.6% | -41.6% | -119.0% | -97.3% | -99.5% | -153.7% |
| Current ratio | 5.53 | 14.99 | 17.61 | 21.23 | 45.18 | 2.73 | 10.83 | 3.96 | 6.45 | 3.11 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $4.90M | $4.78M | $6.16M | $5.37M | $5.50M | $4.16M | $3.40M | $3.41M | $3.55M | $3.75M | $5.65M | $4.47M |
| Selling, general and admin | $3.80M | $5.09M | $5.28M | $3.88M | $3.54M | $3.26M | $3.75M | $2.97M | $3.55M | $3.23M | $3.37M | $3.00M |
| Operating income | -$8.69M | -$9.87M | -$11.44M | -$9.25M | -$9.04M | -$7.41M | -$7.15M | -$6.38M | -$7.11M | -$6.98M | -$9.02M | -$7.47M |
| Pre-tax income | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | -$6.72M | -$6.35M | -$7.23M | -$6.05M | -$5.88M | -$7.75M | -$6.23M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | -$6.72M | -$6.35M | -$7.23M | -$6.05M | -$5.88M | -$7.75M | -$6.23M |
| EPS, basic | -$0.95 | -$1.11 | -$1.23 | -$1.05 | -$0.98 | -$0.78 | -$0.64 | -$0.90 | -$0.75 | -$0.75 | -$0.90 | -$0.75 |
| EPS, diluted | -$0.95 | -$1.11 | -$1.23 | -$1.05 | -$0.98 | -$0.78 | -$0.64 | -$0.90 | -$0.75 | -$0.75 | -$0.90 | -$0.75 |
| Diluted shares | 8.9M | 8.6M | - | 8.6M | 8.6M | 8.6M | - | 8.4M | 8.4M | 8.4M | - | 8.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $26.09M | $31.72M | $41.30M | $51.84M | $57.86M | $65.12M | $71.08M | $74.77M | $79.53M | $83.96M | $88.46M | $94.03M |
| Current assets | $31.01M | $36.67M | $45.62M | $55.68M | $62.52M | $68.74M | $74.46M | $77.11M | $81.72M | $87.06M | $92.22M | $97.65M |
| Total assets | $32.28M | $37.94M | $47.61M | $58.01M | $64.52M | $70.75M | $76.44M | $79.48M | $85.86M | $91.09M | $96.25M | $101.69M |
| Current liabilities | $5.45M | $7.46M | $8.26M | $8.22M | $6.82M | $5.42M | $4.97M | $5.80M | $5.70M | $5.33M | $5.24M | $3.44M |
| Total liabilities | $5.45M | $7.46M | $8.26M | $8.22M | $6.82M | $5.42M | $4.97M | $5.80M | $5.70M | $5.33M | $5.24M | $3.44M |
| Shareholders' equity | $26.83M | $30.49M | $39.35M | $49.79M | $57.70M | $65.32M | $71.48M | $73.68M | $80.16M | $85.76M | $91.02M | $98.25M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.64M | -$9.58M | -$10.54M | -$6.00M | -$7.26M | -$5.96M | -$7.05M | -$4.75M | -$4.53M | -$4.70M | -$5.57M | -$3.88M |
| Capital expenditures | $0 | $0 | $7.0K | $7.0K | $0 | $9.0K | $0 | $10.0K | $3.0K | $6.0K | $0 | $1.0K |
| Free cash flow | -$9.64M | -$9.58M | -$10.55M | -$6.01M | -$7.26M | -$5.97M | -$7.05M | -$4.76M | -$4.53M | -$4.70M | -$5.57M | -$3.88M |
| Investing cash flow | $0 | $0 | -$7.0K | -$7.0K | $0 | -$9.0K | $0 | -$10.0K | -$3.0K | -$6.0K | $0 | -$1.0K |
| Financing cash flow | $4.02M | $0 | $0 | $0 | $0 | $0 | $3.37M | $0 | $100.0K | $204.0K | $0 | -$1.48M |
| Share repurchases | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Stock-based compensation | $815.0K | $722.0K | $503.0K | $784.0K | $796.0K | $563.0K | $774.0K | $749.0K | $352.0K | $417.0K | $519.0K | $926.0K |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | - | - | $3.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.69 | 4.92 | 5.53 | 6.77 | 9.17 | 12.67 | 14.99 | 13.30 | 14.35 | 16.34 | 17.61 | 28.35 |
Source: XBRL data Atossa Therapeutics Inc. files with the SEC, latest filing dated Aug 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported May 14, 2018; 1-for-15, first reported Mar 25, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ATOS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ATOS | - | - | -$37.71M | - | $21.3M |
| ARVN | $275.30M | -11.8% | -$9.50M | -3.5% | $442.7M |
| OLMA | - | - | -$204.57M | - | $644.0M |
| CELC | - | - | -$256.01M | - | $3.46B |
| RLAY | $10.35M | +23.9% | -$293.63M | -2837.0% | $4.51B |
| PBYI | $231.82M | +9.4% | $23.83M | 10.3% | $433.6M |
ATOS FAQ
6 questionsIs ATOS profitable?
No. Atossa Therapeutics Inc. reported a net loss of $37.71M for the twelve months ended Jun 30, 2026.How much cash and debt does ATOS have?
Atossa Therapeutics Inc. reported $26.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ATOS free cash flow?
Atossa Therapeutics Inc. generated -$35.78M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$35.77M less capital expenditures.What is ATOS earnings per share?
Diluted earnings per share were -$4.34 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did ATOS last report financial results?
The latest statements here come from Atossa Therapeutics Inc.'s 10-Q filed on Aug 7, 2026, covering the period ended Jun 30, 2026.Where does this ATOS financial data come from?
Quantisnow builds these statements from the structured XBRL data Atossa Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.